Do More Single Cell with Less

Level Up Your Heme-onc Research

There’s a new update to the Tapestri Platform, the only single-cell DNA and multi-omics solution that analyzes genotype and phenotype simultaneously from single cells.

With the latest additions and improvements to Tapestri’s capabilities, researchers of hematologic oncology can now access single-cell insights from as few as 20,000 cells, while conserving precious samples. Get up and running quickly with single-cell experiments with our expanded menu for hematologic malignancies. Now you can do more single cell in less time with lower sample input, enabling new avenues for your research that were previously impossible.

INSIGHTS FROM 20K CELL INPUT

Low Input, Big Insights

With our new input requirements down to as few as 20,000 cells, perform single-cell analysis on projects where it wasn’t previously possible, all the while conserving precious samples. Get insights from low input samples without sacrificing performance and the ability to detect rare cells.

Consistent variant signatures and sensitivity observed in low (20k, left) and high (100k, right) inputs of three cell lines. The cell line GM12878 (spiked-in at 5% concentration) is detected consistently, demonstrating that the ability to detect cell populations is unaffected by cell input amounts.

Consistent scDNA-seq performance observed across a range of cell inputs from 20k to 100k cells, as demonstrated by the consistent capture rate of >5% (left) and high panel uniformity of >90% (right) across the range.

READY-TO-USE CONTENT

Expanded Menu for Heme Malignancies

Get up and running quickly and conveniently thanks to pre-designed panels for heme malignancies. The new Tapestri Single-cell DNA Published Panels are sourced from leading researchers covering various indications. These have been featured in peer-reviewed publications, verifying performance.

For simultaneous single-cell DNA and protein analysis, configure your own antibody cocktail from a growing catalog of pre-optimized antibody oligonucleotide conjugates (AOC). Or, start with the pre-designed 45-protein TotalSeq™-D Heme Oncology Cocktail, and then spike in additional AOCs to fit your research needs. TotalSeq™ oligo-conjugated antibodies from BioLegend integrate seamlessly into the Tapestri single-cell DNA sequencing workflow to amplify the power of single-cell analysis.

Tapestri Single-cell DNA Published Panels for Hematologic Malignancies

Acute Lymphoblastic Leukemia Published Panel

Publication: Albertí-Servera, L. et al. Blood (2021)
‍
Targeting 112 genes with 305 amplicons

Learn more

Myeloproliferative Neoplasms
Published Panel

Publication: Thompson, E.R. et al. Haematologica (2020)

Targeting 18 genes with 70 amplicons

Learn more

Myeloid Clonal Evolution Published Panel

Publication: Miles, L. A. et al. Nature (2020)

Targeting 32 genes with 109 amplicons

Learn more

Protein Panels for Hematologic Malignancies

BioLegend TotalSeq-D Heme Oncology Cocktail

Target 42 heme cell surface lineage marker antibodies and 3 negative isotype controls

Learn more

BioLegend TotalSeq-D Antibody Oligonucleotide Conjugates

Configure an antibody cocktail from a catalog of pre-optimized antibody oligonucleotide conjugates

Browse

Novel Multi-omics Applications

Profiling hematologic malignancies using single-cell analysis lends insight into how we can better detect and surveil disease, segment patients into clinical trials, and combat resistance to therapies. Investigators have been using the Tapestri Platform to make strides in hematologic oncology research, with breakthrough applications including therapy resistance, clonal hematopoiesis of indeterminate potential (CHIP), and minimal residual disease (MRD). For example, single-cell DNA + protein multi-omics can be leveraged to distinguish MRD from CHIP clones.